ACTRN12615000060549已完成未知
Prospective clinical trial assessing subsidence and rotation after Paragon hip stem arthroplasty in patients with a primary diagnosis of non-inflammatory degenerative joint disease
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 21 Years 至 85 Years（—）
- 性别
- All
入选标准
- •The individual clinically qualifies for a primary total hip replacment using the Paragon cementless hip stem study prosthesis.
- •The individual has a primary diagnosis of non-inflammatory degenerative joint disease.
- •The individual has signed a study specifc informed consent.
- •The individual is physically and mentally willing and able to comply with pre-operative and post-operative assessments and procedures.
排除标准
- •The individual has an active infection within the affected hip joint.
- •The individual has had a previous total hip replacement or hip fusion to the affected hip joint.
- •The individual has a neuromuscular or neurosensory deficit which limits the ability to assess the performance of the prosthesis.
研究者
相似试验
已完成
Unknown
Clinical trial for sacral pressure soreKCT0009002Dankook Univeristy Hospital38
已完成
不适用
A clinical trial to evaluate the effect of improving allergy-like symptoms: A randomized controlled trial.Healthy adultsJPRN-UMIN000016220ORTHOMEDICO, Inc.60
尚未招募
不适用
Preparation of treatment satisfaction tool on selected aspect of nursing to assess the treatment satisfaction of patients receiving chemotherapy and use of FACT G tool to assess quality of life of patients receiving chemotherapy among adult solid tumors at Tata Memorial HospitalCTRI/2020/03/024008Tata Memorial Hospital
招募中
2 期
PICASSO. Prospective randomIzed clinical trial assessing the tolerance and clinical benefit of feCAl tranSplantation in patientS with melanOma treated with CTLA-4 and PD-1 inhibitorsMelanoma2024-516100-42-00Assistance Publique Hopitaux De Paris70
已完成
不适用
clinical trial of weight management supplementatioCTRI/2022/01/039232aturedge Beverages Pvt Ltd30